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Abstract
Background: Quality of life in prostate cancer patients with clinically localized disease has become the focus
of increasing attention over the past decade. However, few instruments have been developed and validated
to assess quality of life speci®cally in this patient population. Objective: The purpose of this investigation
was to create a comprehensive, multi-scale quality of life instrument that can be tailored to the needs of the
clinician/investigator in multiple settings. Design, subjects, and measures: Patients diagnosed with clinically
localized prostate cancer were mailed a questionnaire consisting of new and previously validated quality of
life items and ancillary scales. Data from returned questionnaires were analyzed and used to create a multi-
scale instrument that assesses the eects of treatment and disease on urinary, sexual, and bowel domains,
supplemented by a scale assessing anxiety over disease course/eectiveness of treatment. The instrument
was then mailed to a second sample of prostate cancer patients once and then again two weeks later to
assess test±retest reliability. To assess feasibility in clinical settings, the instrument was self-administered to
a third patient sample during a urology clinic visit. Results: All scales exhibited good internal consistency
and test±retest reliability, convergent and discriminant validity, and signi®cant correlations with disease
speci®c, generic health-related, and global measures of quality of life. Men with greater physiologic im-
pairment reported more limitations in role activities and more bother. Scales were also able to dierentiate
patients undergoing dierent therapies. All scales exhibited negligible correlations with a measure of so-
cially desirable responding. Additionally, the instrument proved feasible when used as a self-administered
questionnaire in a clinical setting. Conclusions: The current instrument possesses brief multi-item scales
that can be successfully self-administered in multiple settings. The instrument is ¯exible, relatively quick,
psychometrically reliable and valid, and permits a more comprehensive assessment of patients' quality of
life.
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Introduction
Treatment decisions for clinically localized pros-
tate cancer, which aected over 110,000 American
men in 1999 [1], are the subject of considerable
controversy [2]. Controversy arises, in part, be-
cause aggressive therapy is often accompanied by
side-eects and complications [3±6] that can sig-
ni®cantly reduce patients' quality of life [7, 8].
Recent decision-analytic studies suggest that when
the adverse impact of incontinence, impotence and
other treatment-related morbidity on quality-Supported in part by the American Urological Association.
Quality of Life Research 9: 645±665, 2000.
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adjusted life years is taken into account, some
classes of patients will achieve greater bene®t by
foregoing aggressive treatment [9]. Because of
these and related ®ndings, most clinicians and re-
searchers advocate discussing with patients the
potential impact on quality of life when making
treatment decisions [10]. Fueling this recommen-
dation is the recognition that quality of life vari-
ables can be measured in a rigorous manner [11±
14] as well as an awareness that third party payers
are beginning to consider impact of treatment
on quality of life when making reimbursement
decisions [13].
The physician who attempts to discuss quality of
life issues with prostate cancer patients in a real-
istic yet reassuring way, however, is faced with a
daunting task. Whereas several quality of life in-
vestigations have suggested that treatment-associ-
ated morbidity is generally well tolerated by
patients [3, 5, 15±18], agreement on this point is
not universal [7, 8]. Closer examination of these
studies reveals substantial dierences in patient
samples and methodology, suggesting that de®ni-
tive statements regarding post-treatment quality of
life cannot yet be made. More importantly, al-
though information from population-based studies
of the eects of treatment is useful, most clinicians
will need to be knowledgeable about the outcomes
experienced by the patients speci®c to their prac-
tice to render appropriate guidance.
Without an ecient and structured means to
acquire such information, physicians will be un-
able to collect the practices-speci®c outcomes data
needed to render adequate counseling. Although
most clinicians possess some knowledge of the
treatment outcomes experienced by their patients,
a variety of factors prohibit collection of reliable
information about morbidity and the impact of
morbidity on patients' quality of life, with perhaps
the most critical being the lack of time imposed by
the constraints of modern practice.
These problems are compounded by the lack of
validated quality of life instruments speci®cally
targeted at men with localized prostate cancer.
Those that are available are primarily ®rst-gener-
ation instruments designed for large, survey-style
research and may not be appropriate for clinical
settings. For example, although existing instru-
ments use multi-item scales to assess decrements
in urinary, sexual and bowel function, the impact
of these decrements on patients' quality of life is
typically assessed through single-item measures of
bother. Because single item measures often pro-
duce unreliable estimates and suer from lack of
precision [19±21], they may lead to faulty conclu-
sions about the eects of disease and treatment,
especially when used to monitor individual pa-
tients over time. Moreover, bother items by
themselves cannot express why a given patient is
experiencing psychological distress, which limits
the ability of clinicians to render the most appro-
priate and cost-eective care.
Additionally, no instruments targeted at pros-
tate cancer patients with localized disease currently
assess anxiety over disease course and the eec-
tiveness of treatment. Past investigations have
suggested that `cancer worry' aects patients'
quality of life [5]. However, the lack of a validated
measure has prevented reliable assessment of
cancer worry in prostate cancer patients. To what
extent cancer worry is a problem in this population
is currently unknown. Another concern is that
items from previous scales were not tested for so-
cial desirability. Items tapping potentially sensitive
topics (e.g., sexual function) may sometimes elicit
overly positive responses from patients who do not
wish to appear inferior or de®cient in domains
they consider important [22]. This is problematic
because items that elicit socially desirable re-
sponding may produce data that underestimate the
impact of treatment on quality of life.
With theses issues in mind, we developed and
evaluated scales for a disease-speci®c, quality of
life instrument targeted at men treated for local-
ized prostate cancer that can be used in clinical or
research settings. Because a number of rigorous
investigations have recently been performed in this
area, we were able to draw from and build upon
previous work, instead of proceeding from a
vacuum.
We focused much of our eort on the creation of
scales that tap important quality of life domains
that previous instruments do not assess, or assess
only in a limited fashion. However, because some of
the current instrument's scales overlap conceptually
with previously validated scales, we strove to create
measures that correlated with related measures
whenever possible. We also designed the current
instrument so that it could be tailored to the needs
of investigators. With the current instrument,
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researchers and clinicians can decide on a case-by-
case basis which scales to use and whether to pair
scales with additional measures, such as more
generic health-related quality of life scales.
Method
Sample
Three samples were used to create and evaluate the
instrument. The ®rst sample, hereafter referred to
as the primary sample, consisted of 300 prostate
cancer patients randomly selected from a larger,
national sample of patients who had been tracked
longitudinally after undergoing prostate speci®c
antigen screenings during Prostate Cancer
Awareness Week from 1991 to 1994. Details con-
cerning diagnosis and staging have been described
elsewhere [23]. All eligible patients from the larger
sample had received a diagnosis of localized
prostate cancer since their initial screening. Addi-
tionally, a majority of patients in the larger sample
had recently participated in a telephone poll
commissioned by the American Urological Asso-
ciation. During the poll, patients were informed
they would be contacted by mail and asked to
participate in an additional study focusing on
quality of life. A second sample was used to eval-
uate the test±retest reliability of the instrument.
The 200 patients contacted for participation in the
test±retest sample were identi®ed using the urology
clinic records of a large hospital in the southeast
US. All patients in the test±retest sample had been
diagnosed with and treated for clinically localized
prostate cancer. A third group of patients, con-
sisting of a convenience sample of 40 patients at-
tending a urology clinic at a large, urban hospital
in the southern US, was used to determine the
instrument's feasibility in a clinical setting. The
patients self-administered the instrument while
waiting for an appointment with a urologist.
Data collection
For the primary sample, an introductory letter
outlining the goals of the study was ®rst sent out to
patients, after which each patient received a mailed
questionnaire packet with a cover letter assuring
anonymity and $5.00 which patients were free to
keep regardless of whether they returned the
questionnaire. Following a four week interval, any
patients who had not returned the questionnaire
were sent another copy and asked to return it
within two weeks time. No further attempts were
made to secure responses after this second attempt
in order to avoid placing undo burden on patients.
Procedures for the test±retest sample paralleled
the ones used for the original sample, with the
addition of a second mailing occurring two
weeks after the ®rst questionnaire was returned.
Participants in the clinic sample were approached
by a research assistant and asked to complete a
questionnaire.
Instrument development and conceptual
framework
Because the term ``quality of life'' when used in
association with health-related matters is often
ill-de®ned [24], we attempted to construct a multi-
scale quality of life instrument that could serve
diverse purposes. In keeping with prior work [3, 5],
items were ®rst chosen that would permit assess-
ment of two conceptually distinct domains: (1) the
degree of impairment in physiologic function as-
sociated with treatment complications and (2) how
much bother patients experience as a result of im-
pairments in physiologic function. In this context,
bother refers to how much psychological distress
and unhappiness patients experience. An example
item from the former domain is ``Over the past four
weeks, how often have you leaked urine?'' An ex-
ample item from the latter domain is ``Over the past
four weeks, how often has your urinary function
made it dicult to enjoy your life?''
In order to increase the instrument's ability to
explain how impairments in function are related to
bother, items tapping a third, conceptually-distinct
domain were also developed. These items assess to
what extent impairments in physiologic function
limit role activities, speci®cally activities related to
social, physical, occupational, sexual, and rela-
tionship functioning. A sample item from this
domain is ``During the past four weeks, how much
did your urinary function OR your concerns and
feelings about your urinary function limit your
social activities?''
Based on previous investigations [3, 5] and pilot
work, we applied this conceptual approach to the
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organ systems most often aected by treatment for
localized prostate cancer: urinary, sexual and
bowel. For each organ system we developed three
scales, one assessing physiologic impairment, one
assessing limitations in role activities and one as-
sessing bother. Additionally, we developed a sep-
arate scale to assess cancer worry, the amount of
worry and concern patients experience over disease
course and perceived eectiveness of treatment.
Table 1 describes the 10 content areas for which
scales were developed.
For each of the 10 content areas we identi®ed a
broad range of test items from past instruments [3,
5, 25] and from consultations with health care
professionals, including two urologists, an inter-
nist and a psychologist. The test items were ®rst
mailed to a sample of 20 patients treated for
clinically localized prostate cancer who were asked
to provide feedback. On the basis of this feedback,
additional items were constructed and some of the
phrasings of previously generated items were
modi®ed. This process produced 120 Likert-type
test items. The items were targeted at the 8th grade
reading level or lower as assessed by the Flesch-
Kincaid Grade Level score, a standard feature of
most word-processing packages. However, a few
speci®c words (e.g., recurring) may require a
higher level of reading ability. These items and
some additional measures were administered
through a mail-out survey to the primary patient
sample described previously. To reduce potential
order eects, the urinary, sexual and bowel sec-
tions were permuted, so that six dierent versions
of the questionnaire were mailed.
Validation measures
To validate the scales derived from the test items,
several other previously validated measures and
additional items were administered simultaneously
with the test items, including the Prostate Cancer
Index (PCI) [5], a health-related quality of life
measure targeted at prostate cancer patients, the
Medical Outcomes Study 36-item Short Form
Health Survey (SF-36) [26], one of the most
commonly used measures of generic health-related
quality of life, the Positive and Negative Aect
Schedule (PANAS) [27], a 20-item, Likert-type
scale that separately assesses levels of positive
and negative emotion and can be used as a
measure of global quality of life, and the Satis-
faction with Life Scale [28], a global quality of life
Table 1. The 10 scales contained in the current instrument
Scale Number
of items
Information elicited by the Scale
Urinary
Function 5 Severity of urinary dysfunction
Role Activity Limitations 5 How much and which activities are
limited by urinary dysfunction
Bother 4 How much patient is bothered/
distressed by urinary dysfunction
Sexual
Function 7 Severity of sexual dysfunction
Role Activity Limitations 5 How much and which activities are
limited by sexual dysfunction
Bother 6 How much patient is bothered/
distressed by sexual dysfunction
Bowel
Function 7 Severity of bowel dysfunction
Role Activity Limitations 5 How much and which activities are
limited by bowel dysfunction
Bother 4 How much patient is bothered/
distressed by bowel dysfunction
Cancer Worry 4 Anxiety/distress over treatment
eectiveness and disease course
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scale. These quality of life measures were speci®-
cally chosen because they range from the speci®c
(e.g., PCI) to the global (e.g., PANAS). This ap-
proach permits validation along a proximal-distal
continum [29]. If the instrument is valid, its scales
should correlate to a greater degree with other
disease-speci®c measures and less so (although still
signi®cantly) with more global measures of quality
of life. Additionally, the Impression Management
Scale of the Balanced Inventory of Desirable Re-
sponding [22] was included to assess whether any
items elicited socially desirable responding. Several
open-ended questions were also included to solicit
patients' feedback regarding the comprehensibility
and relevance of test items. Additional items were
included to assess demographics, comorbidities
and treatment history.
Analysis
On the basis of psychometric and clinical consid-
erations, the test pool of 120 items was reduced to
52 ®nal items, with each of the 10 scales containing
between 4 and 7 items. Speci®cally, items exhibit-
ing skewed response distributions were ®rst elimi-
nated from future consideration. Within each of
the urinary, sexual and bowel sections, exploratory
factor analysis [30] was then used to select items
for the function and bother scales. After item se-
lection for the function and bother scales, items
addressing limitations in role activities were cho-
sen on the basis of clinical considerations and face
validity. Item±total correlations and impact on
Cronbach's a were used for additional item paring
for all scales. Following the determination of scale
items, linear transformations were used to produce
scale scores ranging from 0 to 100. For all scales,
higher scores denote better outcomes. Item stems
are listed in the Appendix.
From a psychometric perspective, scales should
possess high levels of reliability and construct va-
lidity, especially when used for clinical purposes
[19, 26]. Internal consistency reliability was as-
sessed by computing Cronbach's coecient a for
each scale [31]. Because respondents in the primary
sample were guaranteed anonymity (i.e., all
identifying information was removed from
returned questionnaires), it was not possible to
assess test±retest reliability in the original data set.
To evaluate test±retest reliability, were recruited
an additional sample and mailed them the 52-item
questionnaire once at wave 1 and then again two
weeks later at wave 2. A question asking respon-
dents to report the time needed to complete the
questionnaire packet, several demographics items
and some other exploratory measures not relevant
to the current investigation were included in the
wave 1 questionnaire. Test±retest reliability was
assessed via product moment and intra-class cor-
relations [32].
To assess construct validity, several methods
were employed.
Convergent/discriminant validity was assessed
based on the product moment correlations among
the 10 scales. If the scales are valid, scales within
an organ system should tend to correlate more
highly than scales from dierent organ systems.
Concurrent validity, sometimes referred to as
``known groups validity,'' indicates the ability of a
scale to discriminate between groups that are
known or believed to dier [34]. Concurrent va-
lidity was assessed in two ways. To determine
whether scales were sensitive to dierences in pa-
tients with more vs. less physiologic dysfunction,
product moment correlations were computed be-
tween function and daily limitations and bother
scales within each organ group. To determine if
the scales could dierentiate surgical, radiation
and watchful waiting patients, urinary, sexual and
bowel function scores were each subjected to a
one-way analysis of covariance (ANCOVA) using
treatment type as the independent variable and
age, number of comorbidities and time since di-
agnosis as covariates. Planned comparisons, con-
ducted on the basis of previous ®ndings [4, 5], were
used to assess speci®c dierences among the
treatment means, with the expectation that surgi-
cal patients would be more likely to show impaired
urinary and sexual function and radiation patients
would be more likely to show bowel function
impairments. To assess the eciency of the
function scales' ability to detect dierences across
groups, relative eciency ratios were computed
[35]. Ratios were calculated by taking the F
statistic associated with each function scale over
the F statistic derived from the same analysis
using the relevant PCI scale. Ratios greater (or
less) than one indicate that the current instrument
is a more (or less) ecient measure of between
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group dierences than the PCI. The PCI was used
as a standard of comparison because it possesses
physiologic function scales similar to those of the
current instrument.
Criterion validity was assessed by computing
product moment correlations between scales and
previously validated measures of quality of life. To
assess whether the scale items of the current in-
strument tended to evoke biased responses from
participants because of social desirability con-
cerns, product moment correlations between the
ten scales and a measure of impression manage-
ment were calculated. Feasibility was assessed by
examining how long respondents in the test±retest
sample took to complete the questionnaire and by
assessing participation rate and number of items
left blank in the urology clinic sample. Bowel and
cancer worry scales were not administered to the
clinic sample because none of the sample had un-
dergone radiation and because some of the sample
did not have prostate cancer.
Results
Participants
Response rate in the primary sample was 90%.
The data from 5 patients who reported they did
not have prostrate cancer, 6 patients who failed to
complete the majority of the questionnaire, 45
patients who reported treatment indicative of
metastatic disease (e.g., orchiectomy) and 1 patient
who reported receiving cryotherapy, were excluded
from analysis. Scale scores, self-reported treatment
history and other characteristics of the remaining
212 respondents are presented in Tables 2 and 3.
The participant sample spanned the three major
forms of treatment (e.g., radical prostatectomy,
radiation and watchful waiting), although more
patients reported having undergone surgery than
radiation or watchful waiting, and about 9% re-
ported having received surgery and radiation.
Mean age was about 68, and mean time since di-
agnosis was about 4 years. Most of the sample
classi®ed themselves as white/caucasian and cur-
rently married. The patient sample used for the
test±retest study was similar to the primary
sample, except that average time since diagnosis
was 3 years, mean age was about 65, the racial
composition was 14% black and 86% white, and
the vast majority had been treated surgically.
Eight-two percent of the patient sample responded
to both waves of the test±retest administration.
Participants in the clinic sample were on average
63 years old, and the majority classi®ed themselves
as white/caucasian and currently married. All of
the clinic patients who were asked to complete the
instrument did so.














Did not ®nish high school 14
Completed high school and/or some college 46











Surgery and radiation 9















As reported in Table 4, scale a's in the sample
tended to be high, with most above 0.80. These a's
suggest that the scales are reliable and unidimen-
sional. The internal consistency reliability of the
scales is further supported by the a's from the test±
retest sample. As shown in Table 4, these coe-
cients parallel and at times exceed the coecients
from the original sample.
Test±retest reliability
As depicted in Table 4, the 10 scales exhibit levels
of test±retest reliability that are comparable to or
better than similar health related quality of life
scales. Notably, this holds true whether one
examines the product-moment or intra-class
correlations.
Convergent/discriminant validity
Table 5 presents the product-moment correlation
matrix of the 10 scales from the validation sample.
As can be seen from the matrix, scales within each
organ system area tend to converge (i.e., correlate
more) with one another, whereas scales belonging
to dierent content areas tend to diverge (i.e.,
correlate less) from one another, suggesting that
the 10 scales possess good convergent and discri-
minant validity.
Concurrent validity
The positive correlations in bold in Table 5 also
indicate that patients who experience greater de-
crements in function also show greater limitations
in role activities and increased levels of bother,
compared to patients with less decrement in
function, who report experiencing fewer limita-
tions and less bother. Notably, this holds true
whether urinary-, sexual- or bowel-related vari-
ables are being assessed.
To provide further evidence of concurrent va-
lidity, the physiologic dysfunction scores of those
who had undergone surgery, radiation or watchful
Table 3. Scale scores from the primary sample
Mean SD Range
Urinary function 75 23 0±100
Urinary limitations 91 17 0±100
Urinary bother 80 19 13±100
Sexual function 36 28 0±100
Sexual limitations 82 17 20±100
Sexual bother 60 24 0±100
Bowel function 87 11 36±100
Bowel limitations 98 8 45±100
Bowel bother 86 17 0±100
Cancer worry 73 26 0±100
Theoretical range of all scales is 0±100 with higher numbers
denoting better outcomes.
Table 4. Reliability statistics for each scale
Primary sample Test±retest sample
Cronbach's a Cronbach's a Product-moment Intra-class
Urinary function 0.89 0.90 0.92 0.92
Urinary limitations 0.81 0.91 0.86 0.86
Urinary bother 0.89 0.94 0.92 0.91
Sexual function 0.90 0.87 0.91 0.91
Sexual limitations 0.70 0.79 0.86 0.86
Sexual bother 0.87 0.92 0.87 0.87
Bowel function 0.70 0.63 0.72 0.72
Bowel limitations 0.88 0.91 0.68 0.63
Bowel bother 0.90 0.89 0.68 0.68
Cancer worry 0.80 0.78 0.60 0.59
The Cronbach's a listed for the test±retest sample is the average of the wave 1 a and wave 2 a for each scale.
The test±retest statistic is the product-moment correlation coecient between wave 1 scores and wave 2 scores
for each scale. The intra-class statistic is the intra-class correlation coecient between wave 1 scores and wave
2 scores for each scale.
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waiting were also compared using one-way AN-
COVA. As predicted, surgical patients exhibited
more urinary and sexual impairment and radiation
patients more bowel impairment as depicted in
Table 6. The relative eciency statistics suggest
that two of the three function scales may oer
more ecient measures of physiologic function
than the PCI's function scales and would thus re-
quire fewer subjects to detect a given eect size.
Criterion validity
As Tables 7 and 8 indicate, all 10 scales correlated
as predicted with other measures of health-related
and global quality of life. At the disease-speci®c
level, the function scales correlated highly with the
PCI function scales for each organ system as de-
picted in Table 7. Similarly, the bother scales
correlated highly with the PCI's single-item mea-
sures of bother. The limitations in role activities
scales correlated only moderately with the PCI
scales, suggesting that they tap constructs not as-
sessed by the PCI. In general, however, the high
correlations between the current instrument and
the PCI suggest good criterion validity.
The scales of the current instrument are also as-
sociatedwith those of the SF-36, a globalmeasure of
health status. The 80 possible correlations between
the current instrument's 10 scales and the 8 scales of
the SF-36 were all in the predicted direction and all
but 10 were statistically signi®cant, with the average
correlation coecient being 0.25. The pattern of
correlations tended to support the validity of the
current instrument's scales. For example, the cancer
worry scale correlated most highly with the Mental
Health (r = 0.33) and Role Functioning ± Emo-
tional scales of the SF-36 (r = 0.30), which suggests
that this scale is indeed tapping emotional distress.
The scales of the current instrument also cor-
related with global quality of life measures,
Table 5. Correlation matrix of the 10 scales
UF UL UB SF SL SB BF BL BB CW
Urinary function ±
Urinary limitations 0.33 ±
Urinary bother 0.58 0.56 ±
Sexual function 0.13 0.28 0.28 ±
Sexual limitations 0.15 0.28 0.27 0.50 ±
Sexual bother 0.16 0.31 0.25 0.38 0.63 ±
Bowel function 0.04 0.14 0.30 0.12 0.18 0.17 ±
Bowel limitations )0.02 0.23 0.31 0.12 0.24 0.14 0.50 ±
Bowel bother 0.06 0.19 0.34 0.16 0.17 0.19 0.71 0.60 ±
Cancer worry 0.15 0.15 0.21 )0.02 0.17 0.24 0.14 0.10 0.11 ±
The 10 scales are listed vertically by name and horizontally across the top of the matrix by abbreviation (e.g., UF = Urinary
Function). Correlation coecients in bold indicate the correlations between the function, limitations and bother scales within the same
organ system. All correlation coecients above. 0.13 are signi®cant at the 0.05 level.
Table 6. Function scale means adjusted for age, comorbidities and time since







Urinary function 72a,b 84a 89b 0.003 1.29
Sexual function 32a,b 41a 48b 0.06 0.52
Bowel function 89a 80a,b 91b 0.0002 1.50
Across a row, means with the same superscript dier signi®cantly (p < 0.05) or
marginally signi®cantly (p < 0.07 for the sexual function means) using planned
comparisons. Higher scores indicate better function. Relative eciency scores
greater (less) than one indicate greater (lesser) eciency relative to PCI function
scales.
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speci®cally the PANAS-N, the selection of the
PANAS that assesses negative aect, and the
Satisfaction with Life Scale as shown in Table 8.
Speci®cally, the role limitations and bother scales
all correlated signi®cantly with the Satisfaction
with Life Scale and the PANAS-N.
Evaluation of impression management
Only 2 of the 10 correlations between the instru-
ment's scales and the impression management scale
were signi®cant or marginally signi®cant, and both
of these were small in magnitude (for urinary
function, r = 0.13, p < 0.06; for sexual bother,
r = 0.17, p < 0.02). These ®ndings suggest that
the items used in the current instrument generally
do not evoke social desirability concerns. Respon-
dents are not knowingly misrepresenting them-
selves as better o than they really are.
Feasibility
Average time to complete the wave 1 questionnaire
packet administered to the test±retest sample,
which consisted of the 52-item instrument plus 54
additional items, was 29.48 min (SD = 19.78).
This ®nding suggests that the instrument by itself
would take about 15 min to complete. Addition-
ally, when the urinary and sexual scales were ad-
ministered to the urology clinic sample, no patient
refused to complete the questionnaire and no items
were left blank.







PCI urinary function scale 0.94 0.41 0.66







PCI sexual function scale 0.95 0.51 0.39







PCI bowel function scale 0.92 0.51 0.74
PCI Bowel bother item 0.67 0.51 0.93







Urinary function 0.10 )0.03 0.00
Urinary limitations 0.19 )0.16 0.06
Urinary bother 0.29 )0.20 0.04
Sexual function 0.09 )0.16 0.23
Sexual limitations 0.26 )0.27 0.17
Sexual bother 0.31 )0.27 0.08
Bowel function 0.23 )0.28 0.12
Bowel limitations 0.27 )0.26 0.21
Bowel bother 0.25 )0.28 0.17
Cancer worry 0.18 )0.32 0.07
All correlations >0.14 are signi®cant at the 0.05 level. Higher scores on the PANAS-




If quality of life considerations are to be incorpo-
rated eectively into treatment decisions, clini-
cians/investigators must be able to rigorously
assess quality of life-related outcomes experienced
by patients. Accurate assessment of such outcomes
will allow the provision of more appropriate risk
estimates for complications and enable clinicians
to better apprise their patients of how and to what
extent treatment complications are likely to aect
their lives. Moreover, reliable and valid measures
of function, bother and mediating variables are
necessary to identify the processes that foster
successful adaptation to treatment complications.
Ideally, such measures should be quickly and
easily administered and suitable for use in multiple
settings.
The current instrument possesses many of the
properties that would enable it to perform suc-
cessfully in this capacity. For example, the ma-
jority of the scales possess alphas higher than 0.80,
which indicate the scales produce reliable mea-
surements of their respective constructs. However,
it is also true that the a's for the sexual role limi-
tations in the primary sample and bowel function
scale in the primary and test±retest samples are
slightly lower than would be preferred, although
still in the acceptable range. In the case of the
sexual role limitations scales, this is not necessarily
worrisome as sexual function and concerns about
sexual function are unlikely to limit all role activ-
ities similarly (e.g., impairments in sexual function
are likely to limit relationships activities much
more than physical activities) and thus an ex-
tremely high a for this scale would be surprising.
The a's for the bowel function scale, however, may
indicate that this scale needs further re®nement.
In addition to high levels of internal consistency
reliability, the scales also possess high levels of
test±retest reliability, as indicated by both the
product-moment and the intra-class correlations.
The two types of correlations used to examine
test±retest reliability did not dier much in the
current investigation because the average dier-
ence between wave 1 and wave 2 scores was very
small [32], ranging from 0 to 2.57 points across the
10 scales. The nearly equivalent product-moment
and intra-class correlations suggest that wave 1
and wave 2 scores generally did not dier
systematically, which further underscores the psy-
chometric integrity of the instrument. High test±
retest reliability is important because measures
that produce scores that ¯uctuate over time may
obscure clinically important changes in patients'
quality of life. Thus, instruments intended for use
in a clinical setting to monitor an individual pa-
tients' progress are generally required to produce
relatively stable scores in the absence of true
change [33].
Most of the scales of the current instrument
performed well in this regard, although the test±
retest correlations for the bowel scales were lower
than the urinary or sexual scales. Similarly, the
test±retest coecient for the cancer worry scale
was somewhat lower than the others. This may
indicate a de®ciency in the scale, but it may also
re¯ect the ¯uctuating nature of cancer worry in
this population relative to the other constructs
assessed by the PC-QoL. Cancer worry is likely to
wax and wane according to a variety of situational
factors, such as whether a prostate cancer story
has recently appeared in the media or whether a
PSA test is approaching or has just passed. Thus,
it would surprising if the cancer worry scale ex-
hibited extremely high levels of test±retest reli-
ability due to the labile nature of the variable it
measures.
In terms of validity, the instrument also per-
formed well. All scales exhibited good convergent/
discriminant validity. For example, urinary func-
tion correlated more highly with urinary role lim-
itations and urinary bother than with any other
scales. The same holds true for the other organ
systems, as would be expected if the scales were
valid. The results of the current study also indicate
that the scales possess good concurrent validity.
The ability to discriminate among groups is often a
required characteristic of measures used in clinical
trials and other research-related activities when the
goal is to determine whether one group experiences
better or worse outcomes than another. As evi-
denced by the data in Tables 5 and 6, the bother
and limitations scales are sensitive to dierences in
amount of physiologic dysfunction and the func-
tion scales can discriminate among treatment
groups (e.g., patients treated surgically exhibit
worse urinary and sexual function than radiation
or watchful waiting patients). It is important to
note, however, that this latter ®nding should be
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generalized with caution because the patient
sample used in this investigation was not recruited
to assess dierences across treatment groups per se
(e.g., baseline functioning prior to treatment is
unknown and therefore could not be incorporated
into the relevant analyses).
In terms of criterion validity, the scales per-
formed well as indicated by the high correlations
with their respective counterparts in the PCI. The
relatively high correlations are not surprising given
that both instruments are disease-speci®c and that
several of the PCI items are used in modi®ed form
in the scales of the current instrument (e.g., the
PCI's single item bother measures are contained in
the current instrument's bother scales). The in-
strument's criterion validity is also supported by
the pattern of correlations with the Satisfaction
with Life Scale and the PANAS. The lack of as-
sociation with the PANAS-P, the section of the
PANAS that assesses positive aect, is consistent
with those of past investigations, which tend to
show that health and health concerns are more
strongly associated with negative than with posi-
tive aect [36]. Of additional importance is the
signi®cant correlation between the PANAS-N and
the cancer worry scale, which indicates that the
more concerned patients were over disease course/
treatment eectiveness, the more negative emo-
tions they experienced. This association suggests
that this scale does not indeed tap anxiety, worry
and related negative emotions, thereby supporting
the scale's validity.
Of note, the overall validity of the instrument is
supported by the increasing associations between
its scales and other quality of life instruments as
those other measures range from the distal to the
proximal [29]. This pattern supports the instru-
ment's validity. Because the current instrument
measures eects speci®c to prostate cancer and its
treatment, it should correlate most highly with
similar disease-speci®c measures like the PCI, but
less so with measures that are not disease-speci®c,
like the SF-36 and the PANAS, because many
factors other than prostate cancer aect generic
health-related and global quality of life.
However, most of the scales of the current in-
strument still correlate signi®cantly with the global
quality of life measures used in this study. This is
an important ®nding because it demonstrates that
the eects of treatment on prostate cancer patients
are not trivial. Despite the great variety of factors
that contribute to global quality of life (e.g., rela-
tionship quality, personality, income level, job
satisfaction, overall health, etc.), the eects of
treatment for prostate cancer are of sucient
magnitude to be measurable at the most general
level, even in a patient sample that has had four
years on average to adapt to treatment-related
morbidity.
Taken together, the results suggest that the
current instrument possesses many of the proper-
ties necessary for use as an evaluative/monitoring
instrument in clinical settings or as a discrimina-
tive instrument in research settings. The instru-
ment also extends previous work in several ways.
First, the current instrument oers multi-item
scales assessing bother. This addition is important
because most earlier prostate cancer investigations
examining bother and related variables have used
single item measures [3, 5], which typically lack
precision and do not provide reliable measure-
ments of a construct [19±21, 35]. This is potentially
problematic because the results of single-item
measures from past studies are often used as sup-
port for the proposition that prostate cancer
patients adapt well to complications of aggressive
therapy. Given the de®ciencies inherent in one-
item measures, this conclusion may or may not be
warranted.
For example, as depicted in Table 9, 24% of
respondents endorsed the `no problem' response to
the question ``How big a problem has your sexual
function been for you over the last four weeks?''
All of these patients would have received a perfect
score of 100 if this single item had been used to
assess bother. However, these same patients re-
ceived a mean score of 83 (SD = 18) when their
multi-item score was examined, with multi-item
scores in this group ranging anywhere from 36 to
100. In fact, only 6.3% of patients who would have
received a 100 using the single-item would have
also received a 100 using the multi-item scale.
These patients appear to be experiencing a wide
range of distress and bother related to sexual
function that is not tapped by the syntax of a
single item. The same holds true at every response
level of the single-item measure. Even when the
single-item score is similar to the average multi-
item score, there is still considerable variation ev-
ident in the multi-item scores of patients. Notably,
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this pattern recurs when single and multi-item
measures of urinary and bowel bother are com-
pared, albeit to a lesser extent. This suggests that
multiple items are necessary to assess bother in a
rigorous manner, especially in cases where an in-
dividual patient's score would be used as a basis
for clinical decision making. As demonstrated by
Table 9, using single items as a basis for classifying
individual patients will often lead to incorrect
categorizations.
The importance of assessing bother accurately is
highlighted by the patterns of correlations re-
ported in Table 8, which slow that bother tends to
be more consistently and highly correlated with
other measures of global quality of life than the
function and limitations scales, particularly in the
urinary domain. These ®ndings suggest that valid
and reliable bother scales are necessary to assess
the eect of treatment on patients' quality of life.
A further bene®t oered by the current instru-
ment is the cancer worry scale, which uses items
that are applicable to prostate cancer patients
undergoing aggressive therapy as well as those
who have chosen watchful waiting. As suggested
by past research [5] and by the signi®cant corre-
lations of this scale with the other quality of life
measures in the current study, cancer worry may
aect prostate cancer patients' quality of life.
Thus, it is important to be able measure this do-
main in a valid and reliable manner. As suggested
by the signi®cant correlations between this scale
and the PANAS-N and by its relatively high
Cronbach's a, the 4-item cancer worry scale oers
a quick and valid way to assess patient worry and
concern in this domain.
The development and validation of the limita-
tions in role activities scales for each organ system
also dierentiates the current instrument from
previous eorts. These scales provide a relatively
quick means by which patients can communicate
why they are experiencing diculties tolerating
treatment-related morbidity, which in turn should
facilitate the provision of the most appropriate
and cost-eective follow-up care. For example, if a













Single item: How big of a problem has your sexual function been for you over the last 4 weeks?
Endsoring (%) 23 18 15 18 24
Single-item score 100 75 50 25 0
Mean multi-item score (SD) 83 (18) 74 (13) 62 (15) 45 (15) 36 (19)
Min. 36 45 29 17 0
Max. 100 93 88 78 75
Urinary bother
Single item: How big of a problem has your urinary function been for you over the last 4 weeks?
Endorsing (%) 44 28 14 11 3
Single-item score 100 75 50 25 0
Mean multi-item score (SD) 94 (6) 81 (8) 68 (9) 46 (14) 33 (10)
Min. 69 58 50 17 13
Max. 100 90 83 69 42
Bowel bother
Single item: How big of a problem has your bowel function been for you over the last 4 weeks?
Endorsing (%) 69 18 4 8 9
Single-item score 100 75 50 25 0
Mean multi-item score (SD) 95 (4) 80 (6) 62 (11) 46 (13) 15 (21)
Min. 75 65 48 23 0
Max. 100 90 79 63 30
Single-item score refers to the bother score patients would have received based on their response to the single item. Mean multi-item
score refers to the average bother score received by patient groups endorsing each response option of the single item. Min. and max.
refer to the minimum and maximum multi-item score received by each patient group.
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patient reports signi®cant bother due to high levels
of incontinence following radical prostatectomy,
clamps or pads may be sucient to provide relief if
bother is due to incontinence-induced limitations
in physical activities like playing sports or doing
chores. However, if the patient's emotional distress
is due to incontinence-induced limitations in sex-
ual activities, then further surgery or psychological
counseling may provide the only means to relieve
distress.
Another bene®t oered by the current instru-
ment is the use of scales that were validated against
a measure of impression management. The lack of
or low correlations between the 10 scales and the
impression management measure suggest that so-
cial desirability concerns did not cause patients to
knowingly portray themselves as better o than
they really were, even in regard to potentially
sensitive areas like sexual function. These ®ndings
indicate that the current instrument elicits truthful
reports from patients regarding the eects of
treatment on quality of life.
Some limitations of the current investigation
should be noted. The ®rst is that the psychometric
properties of the current instrument require fur-
ther assessment in additional samples. It is possible
the instrument would perform more poorly on
patient samples that diered on important attri-
butes (e.g., socioeconomic status). The second is
that men who initially chose to undergo PSA
screening during Prostate Cancer Awareness Week
may experience dierent outcomes than other
prostate cancer patients. However, the primary
sample demonstrated a relatively large amount of
variability in most outcomes, suggesting that the
sample was adequate in this respect. Of greater
concern was the racial composition of the primary
sample, which was composed mostly of white pa-
tients. Further research is needed to verify the
validity, reliability and feasibility of the instrument
in non-white patients.
Additionally, because most patients diagnosed
with clinically localized prostate cancer have a
spouse or romantic partner, the current instrument
employs several items that are targeted at men
with partners (e.g., how often did you initiate
sexual activities with a spouse or partner?). Thus,
the instrument may provide less precise scores of
men without partners. However, all items possess
response options that can be endorsed by men
without partners and all scales contain items that
do not involve partners, which should tend to
mitigate any eects of partner status. Finally,
although the majority of the scale a's approached
0.90, which is the criterion typically required of
scales used to monitor and evaluate individual
patients [19], some of the scales did not meet this
standard. This suggests that until further experi-
ence with these measures is obtained, use of some
of the current instrument's scales to monitor
individuals (as opposed to groups) should be
performed with caution.
A ®nal caveat concerning the length of the PC-
QoL should be made before concluding this sec-
tion. The PC-QoL oers several enhancements
over pre-existing measures, but it is also by ne-
cessity longer than similar instruments and may
be more burdensome. Although investigators
have the option of foregoing those PC-QoL scales
that are not relevant to their needs, they should
carefully consider the strengths and weaknesses of
all available measures when choosing an instru-
ment.
However, none of these limitations substan-
tially aects the main ®ndings of this study,
which provide evidence of the current instru-
ment's reliability, validity and feasibility. To in-
crease further the instrument's utility, continual
re®nement is underway and computer-adminis-
tered versions are currently being piloted for use
over the Internet. This process will make inter-
pretable feedback quickly accessible to clinicians/
investigators interested in using the instrument as
a tool to assess outcomes and improve quality of
care.
Conclusion
Currently, few validated instruments exist to assess
how prostate cancer patients with localized disease
are aected by undergoing or foregoing treatment.
Moreover, there is often great disparity in how
quality of life is assessed, which has the eect of
limiting comparisons across studies. By embracing
and building upon elements of past work, we have
created a multi-scale, quality of life instrument
that can be used in multiple settings and can be
tailored to the individual needs of the clinician or
investigator.
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Appendix ± the PC-QoL
The following questions ask about urination and your urinary function
1. Over the past 4 weeks, how often have you leaked urine?
Every day 1
About once a week 2 (Circle one number)
Less than once a week 3
Not at all 4
2. Which of the following best describes your urinary control during the last 4 weeks?
No control whatsoever 1
Frequent dribbling 2 (Circle one number)
Occasional dribbling 3
Total control 4
3. How many pads or adult diapers per day did you usually use to control leakage during the last 4 weeks?
3 or more pads per day 1
1±2 pads per day 2 (Circle one number)
No pads or diapers 3
4. Over the past 4 weeks, if you leaked urine, how much usually comes out?
None 1
A few drops 2 (Circle one number)
Less than a tablespoon 3
More than a tablespoon 4
5. In the past 4 weeks, how often have you dripped or leaked urine when you coughed or sneezed?
None of the time or rarely 1
Less than half the time 2 (Circle one number)
About half the time 3
More than half the time 4
6. During the last 4 weeks, how much did your urinary function OR your concerns and feelings about your urinary function limit
your social activities? (for example, doing things with friends or relatives)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
7. During the last 4 weeks, how much did your urinary function OR your concerns and feelings about your urinary function limit
your physical activities? (for example, walking, lifting, bathing, doing chores, etc. ± these do NOT include sexual activities)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
8. During the last 4 weeks, how much did your urinary function OR your concerns and feelings about your urinary function limit
your occupational activities? (for example, work or volunteer work)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
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9. During the last 4 weeks, how much did your urinary function OR your concerns and feelings about your urinary function limit
your sexual activities (for example, intercourse, masturbation or other sexual activities)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
10. During the past 4 weeks, how did your urinary function OR concerns and feelings about your urinary function aect your close,
emotional relationships? (for example, a relationship with a spouse or partner)
Did not interfere 1
Interfered a little 2
Interfered moderately 3 (Circle one number)
Interfered very much 4
Interfered almost all of the time 5
11. Overall, how big a problem has your urinary function been for you during the last 4 weeks?
No problem 1
Very small problem 2
Small problem 3 (Circle one number)
Moderate problem 4
Big problem 5








13. Over the past 4 weeks, how often have you felt embarrassed or ashamed because of poor urinary function?
Almost all the time 1
Frequently 2
Some of the time 3 (Circle one number)
Rarely 4
Never 5
14. Over the past 4 weeks, how often has your urinary function made it dicult to enjoy your life?
Almost all of the time 1
Frequently 2
Some of the time 3 (Circle one number)
Rarely 4
Never 5
The following questions ask about your sexual functioning. If some of the questions seem too personal, you do not have to answer
them, but providing complete information will help us to better understand any problems you may be experiencing. Please be honest
when answering. Remember, any information you provide will be treated con®dentially
15. How would you describe your erections during the last 4 weeks?
None at all 1
Not ®rm enough for any sexual activity 2 (Circle one number)
Firm enough for masturbation and foreplay only 3
Firm enough for intercourse 4
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16. During the past 4 weeks, how would you rate your level of sexual desire?
Very low 1
Low 2
Moderate 3 (Circle one number)
High 4
Very High 5
17. During the past 4 weeks, how often have you had erections when you were sexually aroused or sexually stimulated in any way?
None of the time or rarely 1
Less than half the time 2
About half the time 3 (Circle one number)
More than half the time 4
Always or almost always 5
18. Have you had intercourse during the last 4 weeks?
No 1
Yes, once 2 (Circle one number)
Yes, more than once 3
19. How would you describe the frequency of your orgasms (climaxes) during the past 4 weeks?
I never had an orgasm when I wanted one 1
I had an orgasm less than half the time I wanted one 2
I had an orgasm about half the time I wanted one 3 (Circle one number)
I had an orgasm more than half the time I wanted one 4
I had an orgasm whenever I wanted one 5
20. How often have you felt sexual desire during the past 4 weeks?
Never 1
Once or twice 2
A few times 3 (Circle one number)
Fairly often 4
Often 5
21. During the last 4 weeks, how often did you initiate or start sexual activities with your spouse or partner?
Never 1
Once or twice 2
A few times 3 (Circle one number)
Fairly often 4
Often 5
22. Overall, how big a problem has your sexual function been for you during the last 4 weeks?
No problem 1
Very small problem 2
Small problem 3 (Circle one number)
Moderate problem 4
Big problem 5
23. During the last 4 weeks, how much did your sexual function OR your concerns and feelings about your sexual function limit your
social activities? (for example, doing things with friends or relatives)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
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24. During the last 4 weeks, how much did your sexual function OR your concerns and feelings about your sexual function limit your
physical activities? (for example, walking, lifting, bathing, doing chores, etc. ± these do NOT include sexual activities)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
25. During the last 4 weeks, how much did your sexual function OR your concerns and feelings about your sexual function limit your
occupational activities? (for example, work or volunteer work)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
26. During the last 4 weeks, how much did your sexual function OR your concerns and feelings about your sexual function limit your
sexual activities (for example, intercourse, masturbation or other sexual activities)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
27. During the past 4 weeks, how did your sexual function OR concerns and feelings about your sexual function aect your close,
emotional relationships? (for example, a relationship with a spouse or partner)
Did not interfere 1
Interfered a little 2
Interfered moderately 3 (Circle one number)
Interfered very much 4
Interfered almost all of the time 5








29. Over the past 4 weeks, how concerned or worried have you been about your ability to function sexually?
Extremely 1
Very 2
Moderately 3 (Circle one number)
A little 4
Not at all 5
30. During the past 4 weeks, how frequently were you concerned about or worried that you would be unable to please a spouse or
partner sexually?
Most of the time 1
Frequently 2





31. Over the past 4 weeks, how often has your sexual functioning made it dicult to enjoy your life?
Most of the time 1
Frequently 2
Some of the time 3 (Circle one number)
Rarely 4
Never 5
32. Over the past 4 weeks, how often have you felt embarrassed or ashamed because of poor
sexual function?
Almost all the time 1
Frequently 2
Some of the time 3 (Circle one number)
Rarely 4
Never 5
The following questions ask about your bowel movements and bowel function. Please be honest when answering
33. How often have you felt like you had to have a bowel movement, but did not during the last 4 weeks?
More than once a day 1
About once a day 2
More than once a week 3 (Circle one number)
About once a week 4
Rarely or never 5
34. How often have you had bowel movements that were loose or liquid (no form, watery, mushy)
during the last 4 weeks?
Never 1
Rarely 2
About half the time 3 (Circle one number)
Usually 4
Always 5
35. How often have you had pain caused by cramps in your abdomen or stomach
during the last 4 weeks?
Several times a day 1
About once a day 2
Several times a week 3 (Circle one number)
About twice a month 4
About once this month 5
Rarely or never 6
36. During the past 4 weeks, how often did you have bleeding with your bowel movements?
None of the time or rarely 1
Less than half the time 2
About half the time 3 (Circle one number)
More than half the time 4
Always or almost always 5
37. How much pain have your bowel movements caused you during the last 4 weeks?
Severe pain 1
Moderate pain 2




38. How often did you have trouble delaying your bowel movements until you could reach a bathroom during the past 4 weeks?
Several times a day 1
About once a day 2
Several times a week 3 (Circle one number)
About twice a month 4
About once this month 5
Rarely or never 6
39. Over the past 4 weeks, how many bowel movements did you usually have during a typical day?
None 1
One or two 2
Three or four 3 (Circle one number)
Five 4
More than ®ve 5
40. During the last 4 weeks, how much did your bowel function OR your concerns and feelings about your bowel function limit your
social activities? (for example, doing things with friends or relatives)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
41. During the last 4 weeks, how much did your bowel function OR your concerns and feelings about your bowel function limit your
physical activities? (for example, walking, lifting, bathing, doing chores, etc. ± these do NOT include sexual activities)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
42. During the last 4 weeks, how much did your bowel function OR your concerns and feelings about your bowel function limit your
occupational activities? (for example, work or volunteer work)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
43. During the last 4 weeks, how much did your bowel function OR your concerns and feelings about your bowel function limit your
sexual activities (for example, intercourse, masturbation or other sexual activities)
Did not limit 1
Limited a little 2
Limited somewhat 3 (Circle one number)
Limited very much 4
Prevented me doing these activities 5
44. During the past 4 weeks, how did your bowel function OR concerns and feelings about your bowel function aect your close,
emotional relationships? (for example, a relationship with a spouse or partner)
Did not interfere 1
Interfered a little 2
Interfered moderately 3 (Circle one number)
Interfered very much 4
Interfered almost all of the time 5
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45. Overall, how big a problem have your bowel movements been for you during the last 4 weeks?
Big problem 1
Moderate problem 2
Small problem 3 (Circle one number)
Very small problem 4
No problem 5








47. Over the past 4 weeks, how often have bowel problems or bowel pain made it dicult to enjoy your life?
Most of the time 1
Frequently 2
Some of the time 3 (Circle one number)
Rarely 4
Never 5
48. Over the past 4 weeks, how concerned or worried have you been about bowel problems or bowel pain?
Extremely 1
Very 2
Moderately 3 (Circle one number)
A little 4
Not at all 5
The next few questions ask about the treatment you received or are receiving for prostate cancer. ***The word `treatment' in the
following questions includes watchful waiting or expectant management (a wait and see approach) as well as surgery, radiation or other
forms of treatment***
49. How concerned have you been about the eectiveness of the treatment you received for your prostate cancer?
Very 1
Moderately 2 (Circle one number)
A little 3
Not at all 4
50. How concerned or anxious have you been that your prostate cancer is being treated in the best way possible?
Very 1
Moderately 2 (Circle one number)
A little 3
Not at all 4
51. How anxious or worried are you about the possibility of your prostate cancer recurring or spreading?
Very 1
Moderately 2 (Circle one number)
A little 3
Not at all 4
52. How concerned are you about how well your health is being monitored by your doctor?
Very 1
Moderately 2 (Circle one number)
A little 3
Not at all 4
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